Physician profile
Elise S Split
NPI 1467417063
$6,579.32
in general payments reported to CMS, 2019-2025
27 companies · $1,058 in 2025
The $1,058 reported for 2025 was more than what 86% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,157 · 2022: $1,168 · 2023: $1,251 · 2024: $947 · 2025: $1,058.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,255.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,255.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,160.80 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $849.51 | 2021-2023 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $705.12 | 2021-2024 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $482.61 | 2023-2025 | Camzyos, Eliquis |
| Alnylam Pharmaceuticals INC. | $411.72 | 2021-2025 | Amvuttra |
| Bayer Healthcare Pharmaceuticals INC. | $388.20 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $328.47 | 2021-2025 | Verquvo |
| Edwards Lifesciences Corporation | $308.95 | 2024-2025 | Pascal |
| Atricure, INC. | $306.43 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $305.89 | 2021-2025 | Jardiance |
| Amgen INC. | $177.70 | 2021-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals Lp | $157.91 | 2021-2025 | Wainua, Farxiga |
| Esperion Therapeutics, INC. | $114.67 | 2021-2025 | Nexletol |
| Kiniksa Pharmaceuticals International, Plc | $110.78 | 2024 | Arcalyst |
| Sanofi-Aventis U.S. LLC | $103.93 | 2022-2023 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $91.56 | 2022-2025 | |
| Amarin Pharma, INC. | $79.88 | 2021-2022 | |
| Novo Nordisk INC | $77.13 | 2022-2025 | Ozempic, Rybelsus |
| Boston Scientific Corporation | $72.95 | 2021-2023 | Watchman Access System |
| Actelion Pharmaceuticals US, INC. | $71.67 | 2022-2024 | Opsumit |
| Medtronic, INC. | $64.23 | 2024 | Mc3 Nautilus(Tm) Ecmo Oxygenator |
| Scpharmaceuticals INC. | $57.80 | 2023-2025 | |
| Abbott Laboratories | $46.11 | 2021 | |
| Impulse Dynamics (USA) INC. | $32.12 | 2023 | Optimizer |
| Philips North America LLC | $29.44 | 2025 | Ambulatory Monitoring & Diagnostics Undivided |
| Cardiva Medical, INC. | $27.89 | 2021 | |
| Lantheus Medical Imaging, INC. | $15.85 | 2023 | Definity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elise Split listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.